Premium
Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial
Author(s) -
Tsutsui Keita,
Kikuchi Katsuko,
Nozawa Keiko,
Takashima Atsuo,
Tsuchiyama Kenichiro,
Namikawa Kenjiro,
Aiba Setsuya,
Yamazaki Naoya
Publication year - 2021
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15836
Subject(s) - medicine , cetuximab , benzoyl peroxide , dermatology , adverse effect , epidermal growth factor receptor , clinical endpoint , panitumumab , clinical trial , colorectal cancer , cancer , chemistry , organic chemistry , polymerization , polymer
The most common adverse event of epidermal growth factor receptor inhibitors, used to treat colorectal, non‐small cell lung, and head and neck cancers, is acneiform eruption, with a profound effect on treatment continuation. Prolonged acneiform eruptions treated with topical corticosteroids, a standard management, may be associated with secondary bacterial infections, thus there is a need for new treatments. We conducted a multicenter, phase II trial to evaluate the efficacy and safety of topical benzoyl peroxide for epidermal growth factor receptor inhibitor‐induced prolonged acneiform eruptions. Patients with colorectal, non‐small lung cell, and head and neck cancers who received epidermal growth factor receptor inhibitors for >10 weeks and had persistent acneiform eruptions were eligible. Topical benzoyl peroxide was applied to the affected area of the face once daily for 8 weeks; a clinical evaluation was performed every 2 weeks. The primary endpoint was a change in acneiform eruption severity evaluated between disease onset and end of the treatment period. The quality of life of patients was assessed using the Dermatology Life Quality Index. Of the 14 enrolled patients, 11 completed the trial. The protocol‐specified grade of acneiform eruptions from baseline to week 8 improved from 2.0 to 1.0 ( P < 0.01). The dermatology life quality index score from baseline to week 8 improved from 3.0 to 1.0 point ( P < 0.01). No patient experienced severe adverse events. Overall, topical benzoyl peroxide may be effective for treating and managing prolonged acneiform eruptions induced by epidermal growth factor receptor inhibitors.